These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 12651267)

  • 21. Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden.
    Graf LL; Welsh CH; Qamar Z; Marlar RA
    Am J Clin Pathol; 2003 Jan; 119(1):52-60. PubMed ID: 12520697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between adverse pregnancy outcomes and maternal factor V G1691A (Leiden) and prothrombin G20210A genotypes in women with a history of recurrent idiopathic miscarriages.
    Mahjoub T; Mtiraoui N; Tamim H; Hizem S; Finan RR; Nsiri B; Almawi WY
    Am J Hematol; 2005 Sep; 80(1):12-9. PubMed ID: 16138341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activated protein C resistance in anterior ischaemic optic neuropathy.
    Nagy V; Facsko A; Takacs L; Balazs E; Berta A; Balogh I; Edes I; Czuriga I; Pfliegler G
    Acta Ophthalmol Scand; 2004 Apr; 82(2):140-3. PubMed ID: 15043529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activated protein C resistance and the FV:R506Q mutation in a random population sample--associations with cardiovascular risk factors and coagulation variables.
    Lowe GD; Rumley A; Woodward M; Reid E; Rumley J
    Thromb Haemost; 1999 Jun; 81(6):918-24. PubMed ID: 10404768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factor V Leiden in pregnancies complicated by placental abruption.
    Procházka M; Happach C; Marsál K; Dahlbäck B; Lindqvist PG
    BJOG; 2003 May; 110(5):462-6. PubMed ID: 12742330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation.
    Brugge JM; Simioni P; Bernardi F; Tormene D; Lunghi B; Tans G; Pagnan A; Rosing J; Castoldi E
    J Thromb Haemost; 2005 Dec; 3(12):2695-702. PubMed ID: 16359508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical evaluation of a new functional test for detection of activated protein C resistance (Pefakit APC-R Factor V Leiden) at two centers in Europe and the USA.
    Schöni R; Quehenberger P; Wu JR; Wilmer M
    Thromb Res; 2007; 119(1):17-26. PubMed ID: 16934314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thrombin generation and D-dimer concentrations in a patient cohort investigated for venous thromboembolism. Relations to venous thrombosis, factor V Leiden and prothrombin G20210A. The LIST study.
    Chaireti R; Jennersjö C; Lindahl TL
    Thromb Res; 2009 Jun; 124(2):178-84. PubMed ID: 19232683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Venous thromboembolism in carriers of the Factor V Leiden mutation and in patients without known thrombophilic risk factor; prediction of recurrence and APC-PCI complex concentration and/or soluble thrombomodulin antigen and activity.
    Strandberg K; Svensson PJ; Ohlin AK
    Thromb Res; 2007; 121(2):145-51. PubMed ID: 17499343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endogenous factor V synthesis in megakaryocytes contributes negligibly to the platelet factor V pool.
    Thomassen MC; Castoldi E; Tans G; Magdeleyns EJ; Delaunoit C; Debusscher L; Van Assche KJ; Rosing J
    Haematologica; 2003 Oct; 88(10):1150-6. PubMed ID: 14555311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A FV multiallelic marker detects genetic components of APC resistance contributing to venous thromboembolism in FV Leiden carriers.
    Mingozzi F; Legnani C; Lunghi B; Scanavini D; Castoldi E; Palareti G; Marchetti G; Bernardi F
    Thromb Haemost; 2003 Jun; 89(6):983-9. PubMed ID: 12783110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of thrombin formation by activated protein C: effect of the factor V Leiden mutation.
    Tans G; Nicolaes GA; Rosing J
    Semin Hematol; 1997 Jul; 34(3):244-55. PubMed ID: 9241709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Congenital and acquired activated protein C resistance.
    Nicolaes GA; Dahlbäck B
    Semin Vasc Med; 2003 Feb; 3(1):33-46. PubMed ID: 15199491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The VITA project: phenotypic resistance to activated protein C and FV Leiden mutation in the general population. Vicenza Thrombophilia and Atherosclerosis.
    Tosetto A; Missiaglia E; Gatto E; Rodeghiero F
    Thromb Haemost; 1997 Aug; 78(2):859-63. PubMed ID: 9268185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel mutation (g2172-->c) in the factor V gene in a Chinese family with hereditary activated protein C resistance.
    Cai H; Hua B; Fan L; Wang Q; Wang S; Zhao Y
    Thromb Res; 2010 Jun; 125(6):545-8. PubMed ID: 20304467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimating the cost of redundancy in molecular diagnostics: the case of activated protein C resistance and factor V Leiden.
    Rolla R; Vidali M; Meola S; Pollarolo P; Pergolini P; Bellomo G
    Clin Lab; 2011; 57(9-10):711-7. PubMed ID: 22029186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ABO blood group but not haemostasis genetic polymorphisms significantly influence thrombotic risk: a study of 180 homozygotes for the Factor V Leiden mutation.
    Procare-GEHT Group
    Br J Haematol; 2006 Dec; 135(5):697-702. PubMed ID: 17107352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
    Gessoni G; Valverde S
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factor V Q506 (resistance to activated protein C) and prognosis after acute coronary syndrome.
    Holm J; Hillarp A; Zöller B; Erhardt L; Berntorp E; Dahlbäck B
    Thromb Haemost; 1999 Jun; 81(6):857-60. PubMed ID: 10404756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factor V:Q506 mutation-resistance to activated protein C (APC): clinical implications with respect to family screening.
    Middeldorp S; van der Meer J
    Semin Thromb Hemost; 1998; 24(4):363-6. PubMed ID: 9763353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.